What is Biocryst Pharmaceuticals Inc's earnings per share (EPS)?

Biocryst Pharmaceuticals Inc (BCRX) reported diluted earnings per share of $1.21 for fiscal year 2025. This represents a 381.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biocryst Pharmaceuticals Inc Financials

BCRX

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Biocryst Pharmaceuticals Inc (BCRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCRX FY2025 2026-05-06

Commercial scale finally outran the cost base, turning a high-gross-margin model into cash that could erase debt.

Between FY2024 and FY2025, revenue nearly doubled while SG&A plus R&D grew far more slowly, so the business crossed a fixed-cost absorption threshold: operating margin swung from -0.6% to 39.0%. Because net income reached $263.9M and operating cash flow reached $347.4M, the profit jump was not just accounting noise; it translated into cash strong enough to clear long-term debt entirely.

With gross margin above 97% in FY2024 and FY2025, manufacturing is not the choke point; the real governor of profit is how much selling and R&D expense the company must carry before revenue scale covers it.

The balance sheet still shows negative equity, but that mostly reflects accumulated past losses rather than current borrowing strain because long-term debt was eliminated in FY2025. That cleanup cut total liabilities by about $333M, while the current ratio remained 2.1x, so liquidity is leaner than earlier cash-heavy years but not obviously squeezed.

Financial Health Signals

Financial Profile 57/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Biocryst Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Biocryst Pharmaceuticals Inc has an operating margin of 39.0%, meaning the company retains $39 of operating profit per $100 of revenue. This results in a moderate score of 51/100, indicating healthy but not exceptional operating efficiency. This is up from -0.6% the prior year.

Growth

100

Biocryst Pharmaceuticals Inc's revenue surged 94.1% year-over-year to $874.8M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

100

Biocryst Pharmaceuticals Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Biocryst Pharmaceuticals Inc's current ratio of 2.06 indicates adequate short-term liquidity, earning a score of 37/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Biocryst Pharmaceuticals Inc has a free cash flow margin of 39.4%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.

Altman Z-Score Grey Zone

2.27

Biocryst Pharmaceuticals Inc scores 2.27, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($2.1B) relative to total liabilities ($633.3M). This signals moderate financial risk that warrants monitoring.

Piotroski F-Score Strong

7/9

Biocryst Pharmaceuticals Inc passes 7 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

1.32x

For every $1 of reported earnings, Biocryst Pharmaceuticals Inc generates $1.32 in operating cash flow ($347.4M OCF vs $263.9M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

4.3x

Biocryst Pharmaceuticals Inc earns $4.3 in operating income for every $1 of interest expense ($341.0M vs $78.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$874.8M

YoY+94.1%

5Y CAGR+117.9%

10Y CAGR+33.6%

Biocryst Pharmaceuticals Inc generated $874.8M in revenue in fiscal year 2025. This represents an increase of 94.1% from the prior year.

EBITDA

$342.4M

YoY+26497.7%

Biocryst Pharmaceuticals Inc's EBITDA was $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 26497.7% from the prior year.

Net Income

$263.9M

YoY+396.9%

Biocryst Pharmaceuticals Inc reported $263.9M in net income in fiscal year 2025. This represents an increase of 396.9% from the prior year.

EPS (Diluted)

$1.21

YoY+381.4%

Biocryst Pharmaceuticals Inc earned $1.21 per diluted share (EPS) in fiscal year 2025. This represents an increase of 381.4% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$344.9M

YoY+749.0%

Biocryst Pharmaceuticals Inc generated $344.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 749.0% from the prior year.

Cash & Debt

$89.7M

YoY-14.3%

5Y CAGR-19.9%

10Y CAGR+12.0%

Biocryst Pharmaceuticals Inc held $89.7M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

213M

YoY+2.2%

5Y CAGR+3.8%

10Y CAGR+11.2%

Biocryst Pharmaceuticals Inc had 213M shares outstanding in fiscal year 2025. This represents an increase of 2.2% from the prior year.

Margins & Returns

Gross Margin

97.8%

YoY+0.5pp

5Y CAGR+6.5pp

10Y CAGR+0.6pp

Biocryst Pharmaceuticals Inc's gross margin was 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.5 percentage points from the prior year.

Operating Margin

39.0%

YoY+39.5pp

5Y CAGR+1020.1pp

10Y CAGR+120.7pp

Biocryst Pharmaceuticals Inc's operating margin was 39.0% in fiscal year 2025, reflecting core business profitability. This is up 39.5 percentage points from the prior year.

Net Margin

30.2%

YoY+49.9pp

5Y CAGR+1056.5pp

10Y CAGR+119.3pp

Biocryst Pharmaceuticals Inc's net profit margin was 30.2% in fiscal year 2025, showing the share of revenue converted to profit. This is up 49.9 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

$166.1M

YoY-4.9%

5Y CAGR+6.2%

10Y CAGR+8.6%

Biocryst Pharmaceuticals Inc invested $166.1M in research and development in fiscal year 2025. This represents a decrease of 4.9% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$2.5M

YoY+119.6%

5Y CAGR+36.9%

10Y CAGR-7.0%

Biocryst Pharmaceuticals Inc invested $2.5M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 119.6% from the prior year.

BCRX Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$874.8M+94.1%	$450.7M+36.0%	$331.4M+22.4%	$270.8M+72.3%	$157.2M+782.4%	$17.8M
Cost of Revenue	$19.1M+55.5%	$12.3M+173.8%	$4.5M-30.1%	$6.4M-11.4%	$7.2M+366.4%	$1.6M
Gross Profit	$855.8M+95.2%	$438.4M+34.1%	$326.9M+23.6%	$264.4M+76.3%	$149.9M+822.0%	$16.3M
R&D Expenses	$166.1M-4.9%	$174.6M-19.4%	$216.6M-14.5%	$253.3M+21.3%	$208.8M+69.8%	$123.0M
SG&A Expenses	$348.6M+30.9%	$266.3M+24.4%	$214.1M+34.3%	$159.4M+34.1%	$118.8M+74.9%	$67.9M
Operating Income	$341.0M+13508.9%	-$2.5M+97.5%	-$103.7M+30.1%	-$148.4M+16.5%	-$177.7M-1.7%	-$174.8M
Interest Expense	$78.9M-19.9%	$98.5M-9.0%	$108.2M+9.2%	$99.1M+67.1%	$59.3M+308.9%	$14.5M
Income Tax	$3.5M+83.2%	$1.9M+521.6%	$310K-88.7%	$2.7M+21.3%	$2.3M	$0
Net Income	$263.9M+396.9%	-$88.9M+60.8%	-$226.5M+8.3%	-$247.1M-34.3%	-$184.1M-0.7%	-$182.8M
EPS (Diluted)	$1.21+381.4%	$-0.43+63.6%	$-1.18+11.3%	$-1.33-29.1%	$-1.03+5.5%	$-1.09

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$156.4M-61.5%	$406.6M+155.1%	$159.4M-2.4%	$163.4M+12.2%	$145.5M+10.6%	$131.5M+12.3%	$117.1M+7.1%	$109.3M
Cost of Revenue	$5.4M-43.5%	$9.5M+335.4%	$2.2M-21.8%	$2.8M-38.7%	$4.6M-25.0%	$6.1M+89.8%	$3.2M+89.0%	$1.7M
Gross Profit	$151.0M-62.0%	$397.0M+152.6%	$157.2M-2.1%	$160.6M+13.9%	$141.0M+12.4%	$125.4M+10.2%	$113.9M+5.8%	$107.6M
R&D Expenses	$60.3M+47.6%	$40.9M-8.4%	$44.6M+2.8%	$43.4M+16.4%	$37.3M-24.6%	$49.4M+20.4%	$41.1M+9.2%	$37.6M
SG&A Expenses	$94.6M-1.3%	$95.8M+15.4%	$83.0M-5.0%	$87.4M+6.0%	$82.5M+2.4%	$80.5M+23.7%	$65.1M+6.3%	$61.2M
Operating Income	-$701.6M-369.4%	$260.4M+779.9%	$29.6M-0.7%	$29.8M+40.3%	$21.2M+570.9%	-$4.5M-158.6%	$7.7M-12.2%	$8.8M
Interest Expense	$19.8M+39.9%	$14.1M-28.1%	$19.7M-8.9%	$21.6M-8.1%	$23.5M-3.9%	$24.4M-1.5%	$24.8M+0.4%	$24.7M
Income Tax	$1.0M-53.8%	$2.2M+382.4%	-$769K-154.9%	$1.4M+93.0%	$726K-9.7%	$804K+37.2%	$586K+240.7%	$172K
Net Income	-$721.8M-393.6%	$245.8M+1805.9%	$12.9M+153.7%	$5.1M+15790.6%	$32K+100.1%	-$26.8M-90.9%	-$14.0M-10.7%	-$12.7M
EPS (Diluted)	$-2.98	N/A	$0.06+200.0%	$0.02	$0.00	N/A	$-0.07-16.7%	$-0.06

BCRX Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$514.2M+4.8%	$490.4M-5.1%	$517.0M-6.0%	$550.0M-6.5%	$588.2M+75.7%	$334.7M
Current Assets	$404.3M-4.2%	$422.0M-14.9%	$496.0M-4.0%	$516.5M-8.8%	$566.1M+74.8%	$323.8M
Cash & Equivalents	$89.7M-14.3%	$104.7M-5.4%	$110.6M-63.7%	$304.8M-39.6%	$504.4M+85.4%	$272.1M
Inventory	$5.4M-33.3%	$8.1M-71.8%	$28.7M+4.2%	$27.5M+74.4%	$15.8M+124.3%	$7.0M
Accounts Receivable	$106.8M+35.1%	$79.1M+38.8%	$57.0M+12.6%	$50.6M+72.0%	$29.4M+240.2%	$8.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$633.3M-34.5%	$966.4M-0.6%	$972.5M+15.1%	$844.6M+21.5%	$695.1M+96.4%	$354.0M
Current Liabilities	$196.1M+22.2%	$160.4M+6.9%	$150.0M+42.1%	$105.5M+1.7%	$103.7M-1.8%	$105.7M
Long-Term Debt	$0-100.0%	$314.9M+3.8%	$303.2M+30.9%	$231.6M+70.2%	$136.1M+13.7%	$119.7M
Total Equity	-$119.2M+75.0%	-$475.9M-4.5%	-$455.5M-54.6%	-$294.6M-175.4%	-$107.0M-455.4%	-$19.3M
Retained Earnings	-$1.5B+14.9%	-$1.8B-5.3%	-$1.7B-15.6%	-$1.5B-20.5%	-$1.2B-18.0%	-$1.0B

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$465.1M-9.6%	$514.2M+15.2%	$446.4M-2.4%	$457.2M-4.8%	$480.0M-2.1%	$490.4M-0.2%	$491.3M+4.0%	$472.4M
Current Assets	$373.6M-7.6%	$404.3M+13.7%	$355.7M-10.7%	$398.5M-2.8%	$410.0M-2.8%	$422.0M-1.2%	$427.1M+17.5%	$363.5M
Cash & Equivalents	$171.6M+91.2%	$89.7M+6.7%	$84.1M-4.5%	$88.0M-16.3%	$105.2M+0.5%	$104.7M+8.1%	$96.8M+23.5%	$78.4M
Inventory	$6.0M+10.9%	$5.4M+3.2%	$5.2M+3.7%	$5.0M-26.6%	$6.9M-15.0%	$8.1M+6.9%	$7.6M+69.9%	$4.5M
Accounts Receivable	$109.3M+2.3%	$106.8M+17.0%	$91.3M+0.2%	$91.2M-2.4%	$93.4M+18.1%	$79.1M+9.1%	$72.5M+5.4%	$68.8M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.0B+60.9%	$633.3M-24.1%	$834.3M-5.1%	$878.8M-5.7%	$932.0M-3.6%	$966.4M+0.7%	$959.8M+1.2%	$948.0M
Current Liabilities	$195.4M-0.3%	$196.1M+3.1%	$190.2M+7.4%	$177.2M+26.7%	$139.9M-12.8%	$160.4M+4.4%	$153.6M+19.0%	$129.1M
Long-Term Debt	$395.2M	$0-100.0%	$194.4M-19.9%	$242.8M-23.0%	$315.4M+0.2%	$314.9M+0.2%	$314.3M+0.2%	$313.8M
Total Equity	-$553.8M-364.8%	-$119.2M+69.3%	-$387.9M+8.0%	-$421.6M+6.7%	-$451.9M+5.0%	-$475.9M-1.6%	-$468.6M+1.5%	-$475.6M
Retained Earnings	-$2.2B-47.9%	-$1.5B+14.0%	-$1.8B+0.7%	-$1.8B+0.3%	-$1.8B0.0%	-$1.8B-1.5%	-$1.7B-0.8%	-$1.7B

BCRX Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$347.4M+767.8%	-$52.0M+45.3%	-$95.1M+41.2%	-$161.8M-13.9%	-$142.2M-5.2%	-$135.1M
Capital Expenditures	$2.5M+119.6%	$1.1M-48.2%	$2.2M+60.5%	$1.4M-43.4%	$2.4M+364.0%	$514K
Free Cash Flow	$344.9M+749.0%	-$53.1M+45.4%	-$97.3M+40.4%	-$163.2M-12.9%	-$144.5M-6.6%	-$135.6M
Investing Cash Flow	-$13.7M-126.0%	$52.6M+140.0%	-$131.5M-2.5%	-$128.2M-911.4%	$15.8M+330.5%	-$6.9M
Financing Cash Flow	-$349.9M-5974.1%	-$5.8M-117.7%	$32.5M-63.1%	$88.0M-75.5%	$359.7M+19.7%	$300.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$61.8M-121.2%	$292.0M+601.4%	$41.6M+0.8%	$41.3M+250.1%	-$27.5M-427.9%	-$5.2M-163.2%	$8.2M+702.7%	-$1.4M
Capital Expenditures	$403K-49.8%	$802K-40.3%	$1.3M+650.8%	$179K+25.2%	$143K-78.8%	$675K+1044.1%	$59K-61.9%	$155K
Free Cash Flow	-$62.2M-121.4%	$291.2M+622.8%	$40.3M-2.0%	$41.1M+248.7%	-$27.7M-369.8%	-$5.9M-171.9%	$8.2M+637.5%	-$1.5M
Investing Cash Flow	-$268.6M-221.8%	-$83.5M-715.1%	$13.6M-53.4%	$29.1M+7.5%	$27.1M+52.2%	$17.8M+109.6%	$8.5M+446.6%	-$2.4M
Financing Cash Flow	$412.6M+289.3%	-$218.0M-270.6%	-$58.8M+20.2%	-$73.7M-14029.3%	$529K+113.2%	-$4.0M-415.6%	$1.3M+164.8%	-$2.0M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

BCRX Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	97.8%+0.5pp	97.3%-1.4pp	98.7%+1.0pp	97.6%+2.2pp	95.4%+4.1pp	91.3%
Operating Margin	39.0%+39.5pp	-0.6%+30.7pp	-31.3%+23.5pp	-54.8%+58.3pp	-113.1%+868.0pp	-981.1%
Net Margin	30.2%+49.9pp	-19.7%+48.6pp	-68.4%+22.9pp	-91.2%+25.9pp	-117.1%+909.2pp	-1026.4%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	51.3%+69.4pp	-18.1%+25.7pp	-43.8%+1.1pp	-44.9%-13.6pp	-31.3%+23.3pp	-54.6%
Current Ratio	2.06-0.6	2.63-0.7	3.31-1.6	4.90-0.6	5.46+2.4	3.06
Debt-to-Equity	0.00+0.7	-0.660.0	-0.67+0.1	-0.79+0.5	-1.27+4.9	-6.22
FCF Margin	39.4%+51.2pp	-11.8%+17.6pp	-29.4%+30.9pp	-60.3%+31.7pp	-92.0%+669.4pp	-761.4%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	96.6%-1.1pp	97.7%-1.0pp	98.6%+0.3pp	98.3%+1.4pp	96.9%+1.5pp	95.4%-1.9pp	97.3%-1.2pp	98.5%
Operating Margin	-448.6%-512.6pp	64.0%+45.5pp	18.6%+0.3pp	18.2%+3.6pp	14.6%+18.0pp	-3.4%-10.0pp	6.6%-1.4pp	8.0%
Net Margin	-461.5%-522.0pp	60.5%+52.4pp	8.1%+5.0pp	3.1%+3.1pp	0.0%+20.4pp	-20.4%-8.4pp	-12.0%-0.4pp	-11.6%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-155.2%-203.0pp	47.8%+44.9pp	2.9%+1.8pp	1.1%+1.1pp	0.0%+5.5pp	-5.5%-2.6pp	-2.9%-0.2pp	-2.7%
Current Ratio	1.91-0.2	2.06+0.2	1.87-0.4	2.25-0.7	2.93+0.3	2.63-0.2	2.78-0.0	2.82
Debt-to-Equity	-0.71-0.7	0.00+0.5	-0.50+0.1	-0.58+0.1	-0.70-0.0	-0.660.0	-0.67-0.0	-0.66
FCF Margin	-39.8%-111.4pp	71.6%+46.3pp	25.3%+0.1pp	25.2%+44.2pp	-19.0%-14.5pp	-4.5%-11.5pp	7.0%+8.4pp	-1.4%

Note: Shareholder equity is negative (-$119.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Avadel Pharmaceu AVDL

$2.1B

Harrow Health Inc HROW

$1.2B

Phibro Animal PAHC

$1.3B

BGM Group BGM

$58.6M

Amphastar Pharma AMPH

$811.8M

Frequently Asked Questions

What is Biocryst Pharmaceuticals Inc's annual revenue?

Biocryst Pharmaceuticals Inc (BCRX) reported $874.8M in total revenue for fiscal year 2025. This represents a 94.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biocryst Pharmaceuticals Inc's revenue growing?

Biocryst Pharmaceuticals Inc (BCRX) revenue grew by 94.1% year-over-year, from $450.7M to $874.8M in fiscal year 2025.

Is Biocryst Pharmaceuticals Inc profitable?

Yes, Biocryst Pharmaceuticals Inc (BCRX) reported a net income of $263.9M in fiscal year 2025, with a net profit margin of 30.2%.

What is Biocryst Pharmaceuticals Inc's EBITDA?

Biocryst Pharmaceuticals Inc (BCRX) had EBITDA of $342.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Biocryst Pharmaceuticals Inc have?

As of fiscal year 2025, Biocryst Pharmaceuticals Inc (BCRX) had $89.7M in cash and equivalents against $0 in long-term debt.

What is Biocryst Pharmaceuticals Inc's gross margin?

Biocryst Pharmaceuticals Inc (BCRX) had a gross margin of 97.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Biocryst Pharmaceuticals Inc's operating margin?

Biocryst Pharmaceuticals Inc (BCRX) had an operating margin of 39.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Biocryst Pharmaceuticals Inc's net profit margin?

Biocryst Pharmaceuticals Inc (BCRX) had a net profit margin of 30.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Biocryst Pharmaceuticals Inc's free cash flow?

Biocryst Pharmaceuticals Inc (BCRX) generated $344.9M in free cash flow during fiscal year 2025. This represents a 749.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Biocryst Pharmaceuticals Inc's operating cash flow?

Biocryst Pharmaceuticals Inc (BCRX) generated $347.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Biocryst Pharmaceuticals Inc's total assets?

Biocryst Pharmaceuticals Inc (BCRX) had $514.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Biocryst Pharmaceuticals Inc's capital expenditures?

Biocryst Pharmaceuticals Inc (BCRX) invested $2.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Biocryst Pharmaceuticals Inc spend on research and development?

Biocryst Pharmaceuticals Inc (BCRX) invested $166.1M in research and development during fiscal year 2025.

How many shares does Biocryst Pharmaceuticals Inc have outstanding?

Biocryst Pharmaceuticals Inc (BCRX) had 213M shares outstanding as of fiscal year 2025.

What is Biocryst Pharmaceuticals Inc's current ratio?

Biocryst Pharmaceuticals Inc (BCRX) had a current ratio of 2.06 as of fiscal year 2025, which is generally considered healthy.

What is Biocryst Pharmaceuticals Inc's debt-to-equity ratio?

Biocryst Pharmaceuticals Inc (BCRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Biocryst Pharmaceuticals Inc's return on assets (ROA)?

Biocryst Pharmaceuticals Inc (BCRX) had a return on assets of 51.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Biocryst Pharmaceuticals Inc's debt-to-equity ratio negative or unusual?

Biocryst Pharmaceuticals Inc (BCRX) has negative shareholder equity of -$119.2M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Biocryst Pharmaceuticals Inc's Altman Z-Score?

Biocryst Pharmaceuticals Inc (BCRX) has an Altman Z-Score of 2.27, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biocryst Pharmaceuticals Inc's Piotroski F-Score?

Biocryst Pharmaceuticals Inc (BCRX) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biocryst Pharmaceuticals Inc's earnings high quality?

Biocryst Pharmaceuticals Inc (BCRX) has an earnings quality ratio of 1.32x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biocryst Pharmaceuticals Inc cover its interest payments?

Biocryst Pharmaceuticals Inc (BCRX) has an interest coverage ratio of 4.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Biocryst Pharmaceuticals Inc?

Biocryst Pharmaceuticals Inc (BCRX) scores 57 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.